TFF2 and prostate neoplasm: These considerations, along with bioinformatics analyses of published gene expression datasets, led us to hypothesize that Sp TFs could be relevant targets in prostate tumors and that the new MTM-A analogues with improved pharmacological properties might be useful for treatment of this disease.